Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04461158
Other study ID # 00095036
Secondary ID 3P30AR072582-03S
Status Completed
Phase N/A
First received
Last updated
Start date September 3, 2020
Est. completion date March 30, 2023

Study information

Verified date February 2024
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To address the health disparities in SLE outcomes for minorities, targeted intervention will be used to address the common barriers to care among patients; a comprehensive patient navigator approach will be utilized based on evidence from prior studies is the purpose of this research. The navigator services most commonly provided include facilitation and coordination of care, practical support, including scheduling transportation and referrals to financial assistance programs, appointment scheduling and reminders, education and psycho-social support. The most effective patient navigators address both health system and patient barriers.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date March 30, 2023
Est. primary completion date March 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Self-identified Minority. 2. Patients = 18 years of age as documented in the electronic medical record. 3. Meeting either American College of Rheumatology or SLICC Classification Criteria for SLE as documented in the electronic medical record. 4. Ability to speak and understand English by self-report. 5. In the past six months having = 1 missed clinic or diagnostic study/laboratory visit as documented in the electronic medical record, or self-reported failure to adhere with prescribed medical therapy for SLE. 6. In the past six months having been prescribed at least one immunosuppressive medication for SLE activity as documented in the electronic medical record regardless of whether taking the medication. 7. Currently enrolled into the Core Center for Clinical Research (CCCR; Pro 00021985) with properly executed Informed Consent Document and HIPAA Authorization. 8. Have telephone access. Exclusion Criteria: 1. Unwilling or unable to give informed consent. 2. Being a prisoner or institutionalized individual. 3. Without telephone access. 4. Do not meet all of the inclusion criteria listed above.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Patient Navigator Services
The navigator services most commonly provided include facilitation and coordination of care, practical support, including transportation and financial assistance, appointment scheduling and reminders, education and psychosocial support

Locations

Country Name City State
United States Medical University of South Carolina Charleston South Carolina

Sponsors (3)

Lead Sponsor Collaborator
Medical University of South Carolina National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement in Medication Adherence Adherence with prescribed medical therapies will be defined as the ratio between the number of therapy-days supplied to the number of days until the prescription was refilled and compared between LPNP participants and usual care patients. Medication adherence rates will be estimated by charts review and comparing these medications to pharmacy records on dates and quantities filled. Included medication classifications will include antihypertensives, immunosuppressants, Plaquenil (hydroxychloroquine), and glucocorticoids. Additionally, overall pill burden will be compared between LPNP participants and usual care patients. LPNP participants' medication diaries will be reviewed to determine self-reported adherence. 12 months - from baseline to 12 month visit
Secondary Improvement in patient-reported lupus-specific disease status Changes in patient-reported lupus-specific disease status (measured by the LupusPRO v1.7) over time, from Baseline, 3, 6, 9, and 12 months, compared between interventional and usual care groups will be completed at the start and end of participation. The LupusPRO is a validated, comprehensive patient reported quality of life questionnaire specific for patients with lupus. Domain areas include: lupus symptoms, cognition, physical health, pain vitality, procreation, emotional health, body image, desires-goals, social support, coping, and satisfaction with care. 12 months - from baseline to 12 month visit
Secondary Improvement in Adherence with medical providers and services Adherence with medical providers and services will be the ratio of number of visits scheduled to the number of visits kept. Rates will be compared between LPNP participants and usual care patients. 12 months - from baseline to 12 month visit
See also
  Status Clinical Trial Phase
Completed NCT02006784 - Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE) N/A
Completed NCT01072734 - Auto-immunity in Lupus Patients After Influenza Vaccine Phase 2
Completed NCT03626311 - Omega-3 Replacement With Krill Oil in Disease Management of SLE N/A
Withdrawn NCT02779153 - Acthar SLE (Systemic Lupus Erythematosus) Phase 4
Completed NCT01992666 - GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus N/A
Completed NCT00779194 - Prospective Study of Rapamycin for the Treatment of SLE Phase 2
Recruiting NCT00582881 - Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus
Terminated NCT02811094 - LUMIER² Study : LUpus Molecular Immunomonitoring to Evaluate the Risk of Relapse N/A
Recruiting NCT05458622 - 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol Phase 3
Recruiting NCT06144710 - SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus Phase 1
Completed NCT03031925 - Detection of Annexin A2 in Systemic Lupus Erythematosus N/A
Not yet recruiting NCT06420154 - The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases Early Phase 1
Recruiting NCT05859997 - Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases N/A
Recruiting NCT02782039 - Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)
Recruiting NCT05567198 - Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
Recruiting NCT05747651 - 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2
Recruiting NCT03030976 - A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE) Phase 1
Recruiting NCT06249438 - A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy Phase 1
Not yet recruiting NCT05724940 - Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus
Recruiting NCT06032923 - Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus Phase 1/Phase 2